New study in GIST

  • 15:38

Immunicum AB (publ) today announced that it, together with Karolinska Institute and Karolinska University Hospital, has filed an application with the Swedish Medical Products Agency to start a phase I/II study with the Company’s therapeutic cancer immune primer INTUVAX®. The safety and efficacy of INTUVAX® in combination with sunitinib in patients with incurable Gastrointestinal Stromal Tumor (GIST) will be examined.

Read the press release here: Press release 150917 – GIST